Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $218.2 million.

  • Akebia Therapeutics' Shares Outstanding (Weighted Average) rose 26.09% to $265.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.1 million, marking a year-over-year increase of 26.09%. This contributed to the annual value of $218.2 million for FY2024, which is 15.81% up from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Shares Outstanding (Weighted Average) is $218.2 million, which was up 15.81% from $188.4 million recorded in FY2023.
  • Akebia Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $218.2 million during FY2024, with a 5-year trough of $144.5 million in FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $196.8 million, with a median of $188.4 million in 2023.
  • Data for Akebia Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 21.05% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Shares Outstanding (Weighted Average) stood at $144.5 million in 2020, then climbed by 21.05% to $175.0 million in 2021, then grew by 5.14% to $184.0 million in 2022, then rose by 2.41% to $188.4 million in 2023, then grew by 15.81% to $218.2 million in 2024.